Moderna 2022 Priorities and Capital Allocation
Overview of bivalent candidates in clinical development
All subjects received mRNA-1273 primary series (100 µg)
Slide 17
Trial
Booster
Dose
Subjects(n)
Phase
mRNA-
2
50 μα
171
•
1273
P201
.
Phase
2/3
P2051
.211
(9 mutations;
50 μα
300
100 μα
595
wild-type and Beta)
.213
50 μα
330
(11 mutations;
100 με
584
Beta and Delta)
•
.214
(32 mutations;
50 μα
425
Phase
3
wild-type and Omicron)
.214
50 μα
(32 mutations;
wild-type and Omicron)
1500
mRNA-1273 has been authorized/
approved for a third or fourth booster
Data for the first bivalent (.211) has
demonstrated superiority against all
VOCs tested (including Omicron and
Delta); also shows durability
improvement for Ancestral, Beta and
Omicron²
Our lead candidate for Fall 2022
booster season is mRNA-1273.214,
combining wild-type and Omicron
P3051
(1) Only showing bivalent arms for the Phase 2/3 and Phase 3 study (2) GMR at 6 months, nominal alpha of 0.05
modernaView entire presentation